The National Cancer Institute (NCI) awarded a $386,470 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Fibroplate Inc. on September 12, 2024. The purpose of this SBIR Phase I project is to assess the efficacy of Fibroplate's proprietary Fibrinoplate-S (FPS) technology, which utilizes fibrinogen-coated albumin nanospheres, in promoting surgical wound healing in breast cancer patients undergoing radiation therapy.
The key objectives of this grant are to: 1) demonstrate FPS's ability to accelerate surgical wound healing after radiotherapy in a murine breast cancer model, and 2) evaluate the safety profile of FPS, including its impact on coagulation parameters and overall health metrics. This research aims to validate FPS's mechanism of action, which involves mobilizing progenitor cells and regulating cytokines, and prepare for a potential Phase II project to further characterize FPS's dosing, efficacy, and safety in additional preclinical studies. If successful, FPS could help shorten the time between surgery and radiation therapy, potentially improving cancer treatment outcomes for patients.
Generated 1/28/25, 8:21 AM